Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
45 hedge funds and large institutions have $12.6M invested in Checkpoint Therapeutics in 2024 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
30% more call options, than puts
Call options by funds: $865K | Put options by funds: $664K
14% more capital invested
Capital invested by funds: $11M → $12.6M (+$1.59M)
13% more funds holding
Funds holding: 40 → 45 (+5)
7.38% less ownership
Funds ownership: 23.63% → 16.26% (-7.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$746K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$321K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$186K |
| 4 |
AI
Atria Investments
Charlotte,
North Carolina
|
+$85.4K |
| 5 |
1WA
180 Wealth Advisors
Federal Way,
Washington
|
+$76.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$374K |
| 2 |
Renaissance Technologies
New York
|
-$345K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$240K |
| 4 |
D.E. Shaw & Co
New York
|
-$112K |
| 5 |
Millennium Management
New York
|
-$43.1K |
CKPT Hedge Fund Activity: Q2 2024 in Review
45 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q2 2024, worth a combined $12.6M — up 14% from $11M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CKPT positions and 4 closed out — a net gain of 6 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $746K. The largest seller was Armistice Capital, cutting an estimated $374K.
- 45 institutional investors held Checkpoint Therapeutics (CKPT) as of Q2 2024, up from 40 in Q1 2024.
- Funds reported $12.6M of Checkpoint Therapeutics stock for Q2 2024, up 14% quarter-over-quarter.
- 10 funds opened new Checkpoint Therapeutics positions in Q2 2024 and 4 closed out, a net change of +6 holders.
- The largest Checkpoint Therapeutics buyer in Q2 2024 was Vanguard Group, an estimated $746K added.
- The largest Checkpoint Therapeutics seller in Q2 2024 was Armistice Capital, an estimated $374K sold.
Based on aggregated 13F filings for Q2 2024.